The Leader in Pharmacogenomics for Therapeutic Development 

Agendia's Credentials

• Proven track record in discovery, identification and validation of new microarray-based gene expression profiles in the field of cancer
• Agendia understands the regulatory requirements of developing companion diagnostics being the first company in the world with a FDA cleared IVDMIA test
• Excellent, fully accredited (CLIA, CAP, FDA and ISO) laboratories for research, development and clinical testing
• Certainty that newly developed tests will be available for patients
• Existing tests on the market:
  -    MammaPrint^® FDA-Cleared gene expression profile for breast cancer prognosis and prediction
  -    TargetPrint^® gene expression analysis for ER, PR, HER status
  -    BluePrint™ molecular subtyping profile for instrinsic tumor subclassification
  -    Research Gene Panel —56 novel drug targets